Calidi Biotherapeutics, Inc. (NYSE American: CLDI) Announces Reverse Stock Split to Boost Investor Appeal

• Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is executing a 1-for-16 reverse stock split effective July 31, 2026.
• This corporate action aims to optimize market dynamics, enhance investor appeal, and ensure compliance with exchange minimum price rules.
• The company's shares will continue trading under the ticker CLDI on a split-adjusted basis, with a new CUSIP number.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a leading biotechnology company that specializes in developing targeted genetic medicine. The company focuses on creating new treatments for diseases. It operates in a competitive field where companies often need to manage their stock to attract and maintain investor interest and meet exchange listing requirements.

Calidi Biotherapeutics has announced a 1-for-16 reverse stock split scheduled for July 31, 2026. A reverse stock split is a corporate action where a company reduces its number of outstanding shares. In this case, every 16 shares of Calidi Biotherapeutics common stock will be combined into one single, more valuable share.

The company's stock will begin trading on a split-adjusted basis when the market opens on July 31, 2026. It will continue to trade under its existing symbol, "CLDI". Following the split, the stock will have a new CUSIP number, which is an identifier for securities, of 320703 507.

This action was approved by stockholders on June 12, 2026. As highlighted by GlobeNewswire, the company's goal is to optimize market dynamics and broaden investor appeal. This is often done to increase the stock price and regain compliance with a stock exchange's minimum price rules, which can make the stock more attractive.

Currently, shares of Calidi Biotherapeutics trade at $0.11, with a market capitalization of approximately $773.50 thousand. The stock's 52-week range has been between a low of $0.10 and a high of $10.92. The recent trading session saw a volume of over 53.60 million shares exchanged, showing significant activity.